Studies have demonstrated that the Presenilin-1/Presenilin-2 conditional double-knockout (DKO) mouse model, created through gene-knockout technology, can replicate the pathological changes observed in clinical AD patients over time. This evidence concerns the gene PSEN1 and Alzheimer disease.